Christina Mattina

A panel assembled at the American Academy of Dermatology 2023 Annual Meeting encouraged the audience of dermatologists to advocate together for needed changes in payment, access, and practice.

Posters presented at the American Academy of Dermatology 2023 Annual Meeting provided a snapshot of disparities in dermatology care, both in terms of geographic differences in access to care and collection of race/ethnicity data in clinical trials.

A pair of posters presented at the American Academy of Dermatology 2023 Annual Meeting showed the efficacy of ruxolitinib cream in improving symptoms of vitiligo on the face, both as assessed by investigators and by how noticeable the patients felt their vitiligo was.

Once thought of as the result of an imbalance in bodily humors, inflammatory skin diseases are now understood to arise from types of immune responses, opening the door to targeted therapies and personalized medicine, according to speakers at the American Academy of Dermatology 2023 Annual Meeting.

Amid a packed roster of of late-breaking research at the American Academy of Dermatology 2023 Annual Meeting, investigators presented findings from long-term extensions of the Topical Ruxolitinib Evaluation in Vitiligo phase 3 studies.

Speakers at the American Academy of Dermatology 2023 Annual Meeting highlighted the potential of DataDerm to tell the story of dermatological care in the United States, but some also cautioned that the registry only reflects those who have access to care in the first place.

A symposium at the American Academy of Dermatology 2023 Annual Meeting convened speakers who presented current data on the use of Janus kinase (JAK) inhibitors in dermatology, including in atopic dermatitis and vitiligo.

The 2023 American Academy of Dermatology Annual Meeting, held in New Orleans, Louisiana, from March 17-21, 2023, will feature research and presentations exploring the mechanisms, presentation, and treatment of dermatological disorders.

Coverage from the 64th Annual American Society of Hematology Meeting and Exposition, December 10-13, 2022, New Orleans, Louisiana.

Amazon’s announcement of a prescription subscription service that charges a flat monthly fee instead of offering discounts on each prescription fill represents the retail giant’s latest foray into the health care space.

During 2022, the FDA approved 2 chimeric antigen receptor (CAR) T-cell therapies for use in second-line treatment, offering new treatment choices but raising the question: What options remain once a patient relapses after CAR T?

Access to and outcomes of chimeric antigen receptor (CAR) T-cell therapies may differ by characteristics such as race, ethnicity, gender, and geographic location among patients with cancer.

In 2022, the articles published in the peer-reviewed The American Journal of Managed Care® (AJMC®) explored care management interventions, savings from biosimilars, and much more.

Our current health care reimbursement system rewards procedures and undervalues the time spent talking with patients and learning their history, which speaks to the need for primary care redesign, according to Vineet Arora, MD, MAPP, dean for medical education at UChicago Medicine.

Individual clinicians can lead efforts to build trust in science and distribute accurate information, but medical schools also have an important role to play in training health care professionals to communicate with the public, according to Vineet Arora, MD, MAPP, dean for medical education at UChicago Medicine.

As dean for medical education at the University of Chicago, Vineet Arora, MD, MAPP, takes a longitudinal view of the training pathway with an eye toward equity in opportunity and system-level improvement of processes.

Vineet Arora, MD, MAPP, dean for medical education at UChicago Medicine, discusses the qualities that led her to nominate Ishani Ganguli, MD, MPH, to receive the Seema S. Sonnad Emerging Leader in Managed Care Research Award. The American Journal of Managed Care® presented the 2022 award to Dr Ganguli at the 2022 Patient-Centered Oncology Care® meeting.

The FDA’s approval of teclistamab for relapsed/refractory (R/R) multiple myeloma makes it the first bispecific T-cell engager antibody to enter the treatment landscape.

Several elements of the Inflation Reduction Act (IRA) align with CMS’ goals of promoting equity through health policy, explained A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.

The Inflation Reduction Act (IRA) temporarily extended Affordable Care Act premium subsidies and instituted an insulin co-pay cap for Medicare beneficiaries, but bipartisan agreement is needed to make these changes permanent and more broadly applicable, explained A. Mark Fendrick, MD.

It's hard to predict whether the Medicare drug price negotiation provision in the Inflation Reduction Act (IRA) could lead to higher or lower prices in the commercial market, said A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.

Most implementations of value-based insurance design (VBID) in commercial markets involve prescription drugs, but some plans are beginning to incorporate cost-sharing offsets, said A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the Center for Value-Based Insurance Design at the University of Michigan.

The Inflation Reduction Act (IRA) contains provisions allowing Medicare to negotiate net prices for prescription drugs, but it remains to be seen whether this will translate into savings for beneficiaries, explained A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.

A search of the peer-reviewed literature turned up inconsistent findings on the effectiveness of corticosteroid irrigation for the treatment of chronic rhinosinusitis (CRS) with nasal polyps.

Congress should build on the value-based insurance design (VBID) elements included in the Inflation Reduction Act to further alleviate the burden of health care costs on Americans, said A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.

Elements inspired by the principles of value-based insurance design (VBID) were incorporated into the recently signed Inflation Reduction Act, which could help reduce costs of care for patients, according to A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.

Despite some differences in the frequency of dermoscopic features between basal cell carcinoma (BCC) and benign skin tumors, dermoscopy alone is not sufficient for a reliable diagnosis, according to a recent study.

A primary analysis of the phase 2 ROSEWOOD trial finds that a combination of zanubrutinib and obinutuzumab is superior to obinutuzumab alone in relapsed/refractory follicular lymphoma (FL). Results were presented at the 2022 European Hematology Association Congress.

The late-breaking oral session at the 2022 European Hematology Association (EHA) Congress allowed investigators to present recently emerging data from abstracts submitted after the deadline, including outcomes from trials in chronic lymphocytic leukemia, multiple myeloma, and sickle cell disease.

During a session at the 2022 European Hematology Association Congress, speakers discussed how artificial intelligence (AI) can help advance the principles of ethical medicine—but also how new technologies are being used to undermine the integrity of scientific research.